Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 84

Merrimack Pharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Merrimack Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Merrimack Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Merrimack Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Merrimack Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Merrimack Pharmaceuticals, Inc. - Brief Merrimack Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Merrimack Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Merrimack Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Merrimack Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Merrimack Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Merrimack Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Merrimack Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Merrimack Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Merrimack Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Merrimack Pharmaceuticals, Inc.; Merrimack Pharmaceuticals, Inc. - Key Therapeutics; Merrimack Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Merrimack Pharmaceuticals, Inc. - News; Merrimack Pharmaceuticals, Inc. - Latest Updates; Merrimack Pharmaceuticals, Inc. - Pipeline; Merrimack Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Merrimack Pharmaceuticals, Inc. Snapshot
Merrimack Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Merrimack Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Merrimack Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Merrimack Pharmaceuticals, Inc. – Pipeline Products Glance
Merrimack Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Merrimack Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Merrimack Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Merrimack Pharmaceuticals, Inc. – Drug Profiles
MM-111
Product Description
Mechanism of Action
R&D Progress
MM-111 + Cisplatin + Capecitabine + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
MM-111 + Herceptin
Product Description
Mechanism of Action
R&D Progress
MM-111 + Lapatinib
Product Description
Mechanism of Action
R&D Progress
MM-111 + Lapatinib + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
MM-111 + Paclitaxel + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
MM-121
Product Description
Mechanism of Action
R&D Progress
MM-121 + Aromasin
Product Description
Mechanism of Action
R&D Progress
MM-121 + Cabazitaxel
Product Description
Mechanism of Action
R&D Progress
MM-121 + Carboplatin
Product Description
Mechanism of Action
R&D Progress
MM-121 + Cetuximab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
MM-121 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
MM-121 + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
MM-121 + Pemetrexed
Product Description
Mechanism of Action
R&D Progress
MM-121 + Tarceva
Product Description
Mechanism of Action
R&D Progress
MM-131
Product Description
Mechanism of Action
R&D Progress
MM-141
Product Description
Mechanism of Action
R&D Progress
MM-151
Product Description
Mechanism of Action
R&D Progress
MM-302
Product Description
Mechanism of Action
R&D Progress
MM-310
Product Description
Mechanism of Action
R&D Progress
MM-398
Product Description
Mechanism of Action
R&D Progress
Merrimack Pharmaceuticals, Inc. – Pipeline Analysis
Merrimack Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Merrimack Pharmaceuticals, Inc. – Pipeline Products By Target
Merrimack Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Merrimack Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Merrimack Pharmaceuticals, Inc. – Recent Pipeline Updates
Merrimack Pharmaceuticals, Inc. - Dormant Projects
Merrimack Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Merrimack Pharmaceuticals, Inc., Recent Developments
Merrimack Pharmaceuticals, Inc.- Press Release
May 30, 2012: Merrimack To Present Data On MM-111 At 2012 ASCO Annual Meeting
May 30, 2012: Merrimack To Present Data On MM-121 At 2012 ASCO Annual Meeting
May 30, 2012: Merrimack To Present Data On MM-302 At 2012 ASCO Annual Meeting
Jan 12, 2012: Merrimack To Present Phase I Results On MM-398 At ASCO 2012 Gastrointestinal Cancers Symposium
Jan 11, 2012: Merrimack Pharmaceuticals Initiates Enrollment In Phase I Study Of MM-151 In Patients With Refractory Advanced Solid Tumors
Oct 01, 2009: Sanofi-aventis And Merrimack Pharmaceuticals Enters A Worldwide Collaboration And Licensing Agreement On MM-121
Jul 06, 2009: Merrimack Pharmaceuticals Initiates Enrollment In A Phase I/II Study Of MM-111
Apr 16, 2009: Merrimack Presents Pre-Clinical Data On MM-121 And MM-111 At The Annual Meeting Of The American Association For Cancer Research
Financial Deals Landscape
Merrimack Pharmaceuticals, Inc., Deals Summary
Merrimack Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Merrimack Pharma Raises $77 Million In Series G Financing
Merrimack Pharma Raises $60 Million In Series F Financing
Merrimack Pharma Raises $65 Million in Series E Financing
Merrimack Pharma Raises $28.3 Million in Series D Financing
Merrimack Pharma Secures $28 Million In Series C Financing
Partnerships
Merrimack Pharma Enters Into Research Agreement With Novartis Institutes for BioMedical Research
Licensing Agreements
Selexis Enters Into Licensing Agreement With Merrimack
Merrimack Pharma Enters Into Licensing Agreement With PharmaEngine
Sanofi-Aventis Enters Into A Licensing Agreement With Merrimack Pharma
GTC Biotherapeutics Enters Into License Agreement With Merrimack Pharma
Selexis Enter Into License Agreement With Merrimack
Codon Devices Enters Into Licensing Agreement With Merrimack Pharma
Equity Offering
Merrimack Pharma Completes IPO For $100 Million
Acquisition
Merrimack Pharma Acquires Hermes Biosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Merrimack Pharmaceuticals, Inc., Key Information
Merrimack Pharmaceuticals, Inc., Key Facts
Merrimack Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Merrimack Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Merrimack Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Merrimack Pharmaceuticals, Inc. – Phase III, 2012
Merrimack Pharmaceuticals, Inc. – Phase II, 2012
Merrimack Pharmaceuticals, Inc. – Phase I, 2012
Merrimack Pharmaceuticals, Inc. – Pre-Clinical, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Merrimack Pharmaceuticals, Inc. - Pipeline By Target, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Merrimack Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Merrimack Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Merrimack Pharmaceuticals, Inc., Deals Summary
Merrimack Pharma Raises $77 Million In Series G Financing
Merrimack Pharma Raises $60 Million In Series F Financing
Merrimack Pharma Raises $65 Million in Series E Financing
Merrimack Pharma Raises $28.3 Million in Series D Financing
Merrimack Pharma Secures $28 Million In Series C Financing
Merrimack Pharma Enters Into Research Agreement With Novartis Institutes for BioMedical Research
Selexis Enters Into Licensing Agreement With Merrimack
Merrimack Pharma Enters Into Licensing Agreement With PharmaEngine
Sanofi-Aventis Enters Into A Licensing Agreement With Merrimack Pharma
GTC Biotherapeutics Enters Into License Agreement With Merrimack Pharma
Selexis Enter Into License Agreement With Merrimack
Codon Devices Enters Into Licensing Agreement With Merrimack Pharma
Merrimack Pharma Completes IPO For $100 Million
Merrimack Pharma Acquires Hermes Biosciences

List of Figures
Merrimack Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Merrimack Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Merrimack Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Merrimack Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Merrimack Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• Abbott Laboratories - IT Sales Opportunities - 2009